-
In the first half of the year, a large number of multinational pharmaceutical companies such as Pfizer, Merck, and BMS maintained growth in performance
Time of Update: 2022-08-15
769 billion, a year-on-year increase of 70% According to Pfizer’s performance report for the first half of 2022, the company achieved total revenue of US$53.
494 billion, a year-on-year increase of 41% after deducting exchange rate effects Merck's 2022 first half financial report shows that the company achieved a total revenue of US$30.
-
Have those pharmaceutical companies that cross the 100 billion medical beauty market become "beautiful"?
Time of Update: 2022-08-15
Among them, in the international market, the financial report shows that in 2021, Sinclair, a subsidiary of Huadong Medicine’s international medical beauty business, will achieve a consolidated operating income of about 665 million yuan, a year-on-year increase of 108.
-
Announcement of pharmaceutical companies listed on the Shenzhen Stock Exchange in August and October: a large number of pharmaceutical companies such as Huadong Medicine and Xinlitai disclose their semi-annual reports
Time of Update: 2022-08-15
Huadong Medicine announced on the same day that the company's wholly-owned subsidiary Zhongmei Huadong will invest no more than 396 million yuan in total to obtain 60% of Huaren Technology by way of capital increase and transfer of shares.
-
Inventory of new drug clinical applications in the first half of the year: anti-tumor drugs are the most popular, the field of diabetes is popular, and the "top three" companies prefer to declare
Time of Update: 2022-08-15
Anticancer drugs are still the hottest From the perspective of drug types, the new drugs applied for clinical use are mainly chemical drugs, with a total of 464, accounting for about 59%; the biological products for therapeutic use are closely followed, with a total of 283, accounting for about 36%; the number of Chinese patent medicines is still small.
-
Enthusiasm for the research and development of oncology drugs is high. This pharmaceutical company has 9 new class 1 tumor drugs approved for clinical use during the year.
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] According to CDE's public information, Hengrui Medicine's HRS-4642 injection has recently been approved for clinical use in KRAS G12D-mutated advanced solid tumors .
-
The seventh batch of successful bidders for centralized procurement "successfully won", and the price is close to the cost?
Time of Update: 2022-08-15
For the sample of auxiliary materials corresponding to the winning bidders listed in the application form 1 (non-bidding companies can also apply) , a maximum of 5000g of samples will be provided at one time according to different types of discounts!
-
In the 100 billion chemical drug market, a new class of drugs is about to emerge
Time of Update: 2022-08-15
power to gain more market According to the industry, from the perspective of pharmaceutical companies accelerating the R&D and innovation of chemical drugs, China's chemical pharmaceutical preparation industry has entered a stage of rapid differentiation, structural upgrading, and elimination of outdated production capacity.
-
The use of essential medicines has been upgraded!
Time of Update: 2022-08-15
What has attracted much attention from the industry is that the new version of the "Operation Manual" further clarifies that the number of varieties of essential drugs purchased and the proportion of their use are included in the assessment points of secondary public hospitals .
-
Levosalbutamol hydrochloride nebulized inhalation solution soared by 3209%!
Time of Update: 2022-08-15
Figure 2: Sales of levalbuterol hydrochloride atomized inhalation solution at terminals in public medical institutions in China (unit: 10,000 yuan)Source: Minet.
Figure 2: Sales of levalbuterol hydrochloride atomized inhalation solution at terminals in public medical institutions in China (unit: 10,000 yuan)Source: Minet.
-
The battle for the "Drug King" is full of thrills and dangers. Can K medicine reach the top? Can ADC become the next legend?
Time of Update: 2022-08-15
Drug K is an anti-tumor drug developed and produced by Merck & Co. As a PD-1 antibody product that has been the focus of academia and industry for a long time, its every move has attracted industry attention from research and development, clinical to marketing, and the continuous expansion of indications.
-
Pharmaceutical companies start a wave of coaching changes, and another chairman resigns!
Time of Update: 2022-08-15
Recently, China Resources Shuanghe announced that Mr. Feng Yi, the chairman of the company, will no longer serve as a director, chairman and chairman of the strategy committee of the company's ninth board of directors since May 11, 2022 because he has reached the statutory retirement age .
-
AI pharma trend sweeps to create a "new normal" for drug research and development
Time of Update: 2022-08-15
The current AI pharmaceutical projects under research are widely distributed in cancer, respiratory system, anti-infection, mental disorders, immune system, ophthalmology, cardiovascular, digestive s
-
The State Food and Drug Administration held a meeting to deploy and deepen the special rectification of drug safety
Time of Update: 2022-08-15
The meeting emphasized that it is necessary to fully implement the spirit of General Secretary Xi Jinping's important instructions, in accordance with the deployment requirements of the first meeting of the State Council's leading group to focus on cracking down on crimes that endanger drug safety, and adhere to the combination of severely cracking down on crimes and strengthening daily supervision and improving long-term mechanisms.
-
13 Class 1 innovative drugs have been approved for marketing!
Time of Update: 2022-08-15
Acceptance in the first half of 2022 According to the latest statistics from Yaozhi data, from January to June 2022, CDE has undertaken a total of 5,850 new drug registration applications (counted by acceptance number, except for review, the same below), including 4,139 for chemical drugs, 740 for traditional Chinese medicine, and 740 for biological products.
-
The continuous promotion of direct settlement of medical insurance across provinces and different places greatly reduces the pressure on patients to advance funds
Time of Update: 2022-08-15
1893 million person-times According to the data provided by the National Medical Insurance Bureau, at present, the cross-provincial direct settlement of hospitalization expenses has reached 57,300 designated medical institutions, which basically cover all the first to third-level designated hospitals.
-
Competition is fierce!
Time of Update: 2022-08-15
com, in 2021, the total sales of isosorbide mononitrate sustained-release tablets in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yuan According to data from Minet.
-
The gourd baby who focuses on children's medicine needs to pay attention to the market changes of Forsythia zhimu!
Time of Update: 2022-08-15
Huluwa Pharmaceutical Focuses on Children's Proprietary Chinese Medicine Huluwa Pharmaceutical has seized the business core of paediatric drugs, and has 34 varieties of paediatric drugs in production and sales in the field of paediatric drugs (all of which have clear usage and dosage for children), Including Pediatric Feire Kechuan Granules, Changyanning Granules/Capsules, Cefixime Dispersible Tablets, Pediatric Paracetamol Huangnamin Granules, Pediatric Cough Syrup, Pediatric Qingyan Granules, etc.
-
MNC semi-annual report: Novartis, Johnson & Johnson, Abbott, Roche "lead the way"!
Time of Update: 2022-08-15
Profits of Novartis and Johnson & Johnson declined; Bojian’s net profit doubled in the second quarter, but the stock market fell; Abbott’s profit increased, but was still negatively affected by the recall and discontinuation of infant formula in February; Roche’s innovative drug performance far exceeded expectations, making up for the disadvantage of “old drugs” .
-
Domestic EGFR inhibitors "kill" intensified!
Time of Update: 2022-08-15
Today, the focus of competition in the market is mainly on the third-generation EGFR inhibitors—— Domestic third-generation EGFR-TKI market Data sources: corporate announcements, public information collation AstraZeneca Osimertinib: Three indications have been approved in China, two of which are covered by medical insurance, and the price has dropped from 51,000 yuan/box/month to the highest reimbursement by medical insurance, and the patient is only responsible for 1,674 yuan/box/month .
-
The innovative drug track is popular, and the enthusiasm for financing of pharmaceutical companies continues to rise
Time of Update: 2022-08-15
The clinical advancement of multiple core pipelines marks the full-speed advancement of Tongyi Medicine's R&D pipeline in the dual-ligand drug coupling technology platform (Bi-XDC) According to the announcement, the financing funds will be mainly used for the clinical development of Tongyi Bi-XDC pipeline, including CBP-1008 China key registration phase II clinical trial, CBP-1018 China-US clinical phase I/II trial, CBP-1019 China-US clinical trial Phase I clinical trials, CBP-8088 (C-PROTAC) Sino-US IND application, etc.
